SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

U. S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI as the first FDA-approved ready-to-use oral suspension COMMACK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office (USPTO) has granted its third patent covering ARBLI (losartan potassium) oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan.